A clinical trial of TRPV4 blockers and their promising roles in the treatment of dyspnea and pulmonary edema in heart failure and acute decompensated heart failure cases is currently finished in phase 1 stage (GlaxoSmithKline, 2019). Here, TRPV4 is linked to heart failure.